Soulen M C
University of Pennsylvania School of Medicine, Philadelphia.
Oncology (Williston Park). 1994 Apr;8(4):77-84; discussion 84, 89-90 passim.
Chemoembolization has several theoretical advantages over intravenous or intraarterial infusion therapy for treatment of primary or metastatic liver tumors. This technique delivers highly concentrated drugs to the tumor, then arrests blood flow. This renders the tumor ischemic, while achieving a drug concentration in the tumor 10 to 25 times greater than can be achieved by infusion. The dwell time for the drug is markedly prolonged, with measurable drug levels present in tumor as long as a month after chemoembolization. Up to 85% of the administered drug is trapped in the liver, minimizing systemic toxicity. Worldwide experience has established chemoembolization as the treatment of choice for unresectable hepatoma. Metastatic lesions from ocular melanoma, neuroendocrine tumors, and sarcomas have been reported to respond well to chemoembolization. The technique also shows promise against colorectal metastases.
对于原发性或转移性肝肿瘤的治疗，化疗栓塞相对于静脉内或动脉内灌注疗法具有几个理论上的优势。该技术将高浓度药物输送到肿瘤，然后阻断血流。这使肿瘤缺血，同时使肿瘤内的药物浓度比灌注所能达到的浓度高10至25倍。药物的停留时间显著延长，化疗栓塞后长达一个月肿瘤内仍存在可测量的药物水平。高达85%的给药药物被困在肝脏中，将全身毒性降至最低。全球经验已将化疗栓塞确立为不可切除肝癌的首选治疗方法。据报道，眼黑色素瘤、神经内分泌肿瘤和肉瘤的转移病灶对化疗栓塞反应良好。该技术对结直肠癌转移也显示出前景。
